Frontiers in Oncology (Jul 2022)

Highly Invasive Fluorescent/Bioluminescent Patient-Derived Orthotopic Model of Glioblastoma in Mice

  • Diana Yuzhakova,
  • Elena Kiseleva,
  • Marina Shirmanova,
  • Vladislav Shcheslavskiy,
  • Vladislav Shcheslavskiy,
  • Daria Sachkova,
  • Daria Sachkova,
  • Ludmila Snopova,
  • Evgeniya Bederina,
  • Maria Lukina,
  • Maria Lukina,
  • Varvara Dudenkova,
  • Gaukhar Yusubalieva,
  • Gaukhar Yusubalieva,
  • Tatyana Belovezhets,
  • Daria Matvienko,
  • Vladimir Baklaushev,
  • Vladimir Baklaushev

DOI
https://doi.org/10.3389/fonc.2022.897839
Journal volume & issue
Vol. 12

Abstract

Read online

Development of the novel diagnostic and therapeutic approaches in neuro-oncology requires tumor models that closely reproduce the biological features of patients’ tumors. Patient-derived xenografts (PDXs) are recognized as a valuable and the most “close-to-patient” tool for preclinical studies. However, their establishment is complicated by the factors related to both the surgical material and technique of the orthotopic implantation. The aim of this work was to develop a patient-derived glioblastoma multiform (GBM) model that stably co-expresses luciferase and a far-red fluorescent protein for monitoring of tumor progression in the brain and, using this model, to validate new diagnostic methods—macroscopic fluorescence lifetime imaging (macro-FLIM) and cross-polarization optical coherence tomography (CP OCT). The established model was similar to the original patient’s GBM in terms of histological and immunohistochemical features and possessed reproducible growth in nude mice, which could be observed by both fluorescence and bioluminescence imaging. Our results demonstrated the high potential of macro-FLIM and CP OCT for intraoperative differentiation of GBM from the white matter. Thus, the dual-labeled PDX model of GBM proved to be an excellent approach for observation of tumor development by optical methods.

Keywords